Talis Biomedical Corp Stock Gross Profit
Talis Biomedical Corp fundamentals help investors to digest information that contributes to Talis Biomedical's financial success or failures. It also enables traders to predict the movement of Talis Pink Sheet. The fundamental analysis module provides a way to measure Talis Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Talis Biomedical pink sheet.
Talis |
Talis Biomedical Corp Company Gross Profit Analysis
Talis Biomedical's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current Talis Biomedical Gross Profit | (149.4 M) |
Most of Talis Biomedical's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Talis Biomedical Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, Talis Biomedical Corp reported (149.4 Million) of gross profit. This is 106.66% lower than that of the Health Care Equipment & Supplies sector and 109.27% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.55% higher than that of the company.
Talis Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Talis Biomedical's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Talis Biomedical could also be used in its relative valuation, which is a method of valuing Talis Biomedical by comparing valuation metrics of similar companies.Talis Biomedical is currently under evaluation in gross profit category among its peers.
Talis Fundamentals
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (113.60) % | ||||
| Current Valuation | (38.24 M) | ||||
| Shares Outstanding | 1.82 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 52.15 % | ||||
| Number Of Shares Shorted | 17.96 K | ||||
| Price To Book | 0.06 X | ||||
| Price To Sales | 19.57 X | ||||
| Revenue | 412 K | ||||
| Gross Profit | (149.4 M) | ||||
| EBITDA | (60.7 M) | ||||
| Net Income | (62.01 M) | ||||
| Cash And Equivalents | 165.37 M | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 19.67 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 12.51 X | ||||
| Book Value Per Share | 26.68 X | ||||
| Cash Flow From Operations | (53.24 M) | ||||
| Short Ratio | 0.59 X | ||||
| Earnings Per Share | (28.02) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 99 | ||||
| Beta | 1.62 | ||||
| Market Capitalization | 7.98 M | ||||
| Total Asset | 98.34 M | ||||
| Retained Earnings | (539.96 M) | ||||
| Working Capital | 68.91 M | ||||
| Net Asset | 98.34 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Talis Pink Sheet
If you are still planning to invest in Talis Biomedical Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talis Biomedical's history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |